Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Lise L Kjaergard Cochrane
Hepatobiliary Group, Copenhagen Trial Unit, Centre for Clinical
Intervention Research, Copenhagen University Hospital, Department 7102, H:S Rigshospitalet, DK-2100 Copenhagen, Denmark
Correspondence to: L
L Kjaergard Kjaergard{at}ctu.rh.dk
Objective:
To assess the association between
competing interests and authors' conclusions in randomised clinical trials.
What is already known on this topic
Trials of antipsychotic drugs for schizophrenia funded by drug
companies were more likely to show a benefit of treatment It is not known whether other competing interests, such as personal,
academic, or political, are associated with authors' conclusions. What this study adds
The association did not reflect inadequate methodological quality,
greater statistical power, or use of inactive control
interventions Personal, academic, and political competing interests were not
significantly associated with authors' conclusions.
Design:
Epidemiological study of randomised clinical trials published in the BMJ from January 1997 to June
2001. Financial competing interests were defined as funding by for
profit organisations and other competing interests as personal,
academic, or political.
Studies:
159 trials from 12 medical specialties.
Main outcome measures:
Authors' conclusions defined
as interpretation of extent to which overall results favoured
experimental intervention. Conclusions appraised on 6 point scale;
higher scores favour experimental intervention.
Results:
Authors' conclusions were significantly
more positive towards the experimental intervention in trials funded by
for profit organisations alone compared with trials without competing
interests (mean difference 0.48 (SE 0.13), P=0.014), trials funded by
both for profit and non-profit organisations (0.30 (SE 0.10),
P=0.003), and trials with other competing interests (0.45 (SE 0.13),
P=0.006). Other competing interests and funding from both for profit
and non-profit organisations were not significantly associated with
authors' conclusions. The association between financial competing
interests and authors' conclusions was not explained by methodological
quality, statistical power, type of experimental intervention
(pharmacological or non-pharmacological), type of control intervention
(for example, placebo or active drug), or medical specialty.
Conclusions:
Authors' conclusions in randomised
clinical trials significantly favoured experimental interventions if
financial competing interests were declared. Other competing interests
were not significantly associated with authors' conclusions.
Financial competing interests may influence authors' conclusions
for
instance, interpretation of whether results favour the experimental or
control intervention
In pharmacological and non-pharmacological randomised clinical trials
from 12 specialties financial competing interests were significantly
associated with authors' conclusions
© BMJ 2002
Read all Rapid Responses